Key Highlights

  • Net loss per share was USD 0.62, compared with USD 2.01.
  • Net loss was USD 4.23 million, compared with USD 13.59 million.
  • Total operating expenses were USD 5.99 million, compared with USD 15.47 million.
  • Marketable securities were USD 59.53 million at September 30, 2026.

Instil Bio (NASDAQ:TIL) reported a net loss of USD 4.23 million for the third quarter of 2026, compared with USD 13.59 million in the third quarter of 2025. The net loss per share, basic and diluted, was USD 0.62, compared with USD 2.01.

The Quarterly Report did not state a Revenue figure for the period.

Operating Expenses

Research and development expense was USD 0.23 million, compared with USD 9.13 million. General and administrative expense was USD 5.83 million, compared with USD 6.34 million, and restructuring and Impairment charges, net, were a Credit of USD 0.08 million. The filing states that the credit consisted primarily of the Reversal of previously recognized restructuring liabilities associated with contract terminations as the related obligations were settled and extinguished.

Total operating expenses, which equal the loss from operations, were USD 5.99 million, compared with USD 15.47 million.

Interest income was USD 0.62 million, compared with USD 0.89 million, and interest expense was USD 1.55 million, compared with USD 1.58 million. Other rental income was USD 2.70 million, compared with USD 2.69 million.

Nine-Month Results

For the nine months ended September 30, 2026, the net loss was USD 13.02 million, compared with USD 63.50 million, and the net loss per share was USD 1.92, compared with USD 9.58. Research and Development expense was USD 1.17 million, compared with USD 21.24 million, and general and administrative expense was USD 17.51 million, compared with USD 22.69 million. Total operating expenses were USD 19.77 million, compared with USD 70.55 million, and the company recorded a gain on contract termination of USD 1.62 million.

Balance Sheet

Cash and cash equivalents were USD 2.54 million at September 30, 2026, compared with USD 6.64 million at December 31, 2025. Marketable securities were USD 59.53 million, compared with USD 69.49 million. The filing states that cash, cash equivalents, restricted cash, marketable securities and Long-Term Investments totaled approximately USD 67.1 million. Total Assets were USD 195.65 million, compared with USD 204.52 million, and the Loan payable was USD 85.06 million, compared with USD 84.81 million.

The filing states that management evaluated the company's ability to continue as a going concern. The 2024 loan had a scheduled Maturity in January 2027 with total principal of USD 85.6 million, which exceeded cash, cash equivalents, marketable securities and long-term investments on hand at September 30, 2026, and management concluded that this was an indicator of substantial doubt. During the quarter, the company delivered an irrevocable notice of its election to extend the maturity by one year to January 2028, and management concluded that this election alleviates the conditions that raised substantial doubt.

The filing reports 6,781,976 shares of common stock outstanding at September 30, 2026. In March 2025, the Board of Directors approved a plan to sell the Tarzana facility, and assets held for sale were USD 112.10 million at December 31, 2025. Total stockholders' Equity was USD 102.56 million, compared with USD 112.67 million.

Instil Bio Q3 2026 Earnings: Key Takeaways

Instil Bio reported a third quarter 2026 net loss of USD 4.23 million and a loss per share of USD 0.62. Marketable securities were USD 59.53 million at September 30, 2026.